1. "2013"
Formats
  1. Journal Article (2495)
  2. Meeting Abstract (1292)
  3. Book Section (250)
  4. Conference Paper (18)
  5. Book Whole (17)
  6. Review (1)
Groups
  1. Department of Medicine (1421)
  2. GSK Faculty (1000)
  3. Surgery (873)
  4. Solid Tumor Oncology Division (781)
  5. Survivorship Research (671)
  6. Sloan Kettering Institute Faculty (646)

More Groups

People
  1. Jose Baselga (74)
  2. Clifford Hudis (69)
  3. Jedd Wolchok (65)
  4. Howard Scher (62)
  5. Mithat Gonen (62)
  6. Ross Levine (62)

More People

Years
  1. 2013 (4073)
Publications
  1. Journal of Clinical Oncology (366)
  2. Blood (190)
  3. Cancer Research (119)
  4. International Journal of Radiation Oncology, Biology, Physics (88)
  5. Modern Pathology (88)
  6. Laboratory Investigation (81)

More Publications

Publishers
  1. Elsevier Inc. (502)
  2. American Society of Clinical Oncology (386)
  3. Springer (304)
  4. Nature Publishing Group (249)
  5. Elsevier Science, Inc. (206)
  6. American Society of Hematology (192)

More Publishers

Results (4073)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Capanu, M.; Gromisch, C. M.; Kelsen, D. P.; Ku, G. Y.; Brown, K. T.; Schattner, M.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265)
    Meeting Abstract

    King Huh, W.; Brady, W. E.; Moore, K. N.; Lankes, H. A.; Monk, B. J.; Aghajanian, C.; Dizon, D. S.; Fracasso, P. M.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study
    Meeting Abstract

    Hutson, T. E.; Nosov, D.; Harza, M.; Esteves, B.; Strahs, A. L.; Berkenblit, A.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2
    Meeting Abstract

    Ito, Y.; Noguchi, S.; Deleu, I.; Baselga, J.; Hortobagyi, G. N.; Bachelot, T. D.; Masuda, N.; Pistilli, B.; Pritchard, K. I.; Iwata, H.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment
    Meeting Abstract

    Iwata, H.; Baselga, J.; Campone, M.; Arteaga, C. L.; Cortes, J.; Jonat, W.; De Laurentiis, M.; Ciruelos, E.; Janni, W.; Bachelot, T.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses
    Meeting Abstract

    Huse, J. T.; Beal, K.; Zhang, J.; Kastenhuber, E. R.; Kaley, T. J.; Abrey, L. E.; Gutin, P. H.; Brennan, C. W.; Omuro, A. M. P.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers
    Meeting Abstract

    Hong, D. S.; Younes, A.; Fayad, L.; Fowler, N. H.; Hagemeister, F. B.; Mistry, R.; Nemunaitis, J. J.; Borad, M. J.; Bryce, A. H.; Yamashita, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ in patients with relapsed/refractory lymphoma
    Meeting Abstract

    Horwitz, S. M.; Flinn, I.; Patel, M. R.; Younes, A.; Foss, F. M.; Oki, Y.; Sweeney, J.; Allen, K.; Dunbar, J.; Kelly, P. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM)
    Meeting Abstract

    Hu, M. I. N.; Glezerman, I.; Leboulleux, S.; Insogna, K. L.; Gucalp, R. A.; Misiorowski, W.; Yu, B. W.; Zorsky, P.; Tosi, D.; Bessudo, A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)
    Meeting Abstract

    Hauschild, A.; Grob, J. J.; Demidov, L. V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C. U.; Miller, W. H.; Kaempgen, E.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save